Business Context and Reporting Period
This Form 8-K is a current report filed by AVROBIO, Inc. (not Tectonic Therapeutic, Inc.) on April 28, 2023, regarding events occurring on that date and effective May 1, 2023. The filing addresses a significant leadership transition within the company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and personnel changes.
Material Changes
- Resignation of CEO and Director: Geoff MacKay resigned as President, Chief Executive Officer, and member of the Board of Directors, effective May 1, 2023. The resignation is not due to any disagreement with the company.
- Appointment of Interim CEO: Erik Ostrowski, the current Chief Financial Officer and Treasurer, was appointed as President and Interim Chief Executive Officer, effective May 1, 2023. He will retain his CFO and Treasurer roles.
- Compensation Adjustment: The Compensation Committee extended the post-termination exercise period for Mr. MacKay's vested time-based stock options from three months to twelve months.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or discuss specific business risks. It notes that there are no material plans, contracts, or arrangements entered into with Mr. Ostrowski in connection with his appointment. The company issued a press release on May 1, 2023, titled "AVROBIO Announces Leadership Transition," which is included as an exhibit.
Investor Verification Checklist
- Verify the effective date of the leadership transition (May 1, 2023).
- Confirm that the resignation of Geoff MacKay was not related to any disagreement with the company.
- Review the background of the new Interim CEO, Erik Ostrowski, noting his tenure as CFO since January 2019.
- Check for any subsequent filings regarding the search for a permanent CEO.